Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

ClinicalTrials.gov ID: NCT00625664

Public ClinicalTrials.gov record NCT00625664. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

Study identification

NCT ID
NCT00625664
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
337 participants

Conditions and interventions

Interventions

  • larotaxel (XRP9881) Drug
  • gemcitabine Drug
  • cisplatin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2008
Primary completion
Jan 31, 2011
Completion
Jan 31, 2011
Last update posted
May 4, 2016

2008 – 2011

United States locations

U.S. sites
52
U.S. states
26
U.S. cities
49
Facility City State ZIP Site status
Sanofi-Aventis Investigational Site Number 840068 Anchorage Alaska 99508
Sanofi-Aventis Investigational Site Number 840035 Berkeley California 94704
Sanofi-Aventis Investigational Site Number 840012 Burbank California 91505
Sanofi-Aventis Investigational Site Number 840029 La Jolla California 92037
Sanofi-Aventis Investigational Site Number 840046 Los Angeles California 90033
Sanofi-Aventis Investigational Site Number 840003 Sacramento California 95817
Sanofi-Aventis Investigational Site Number 840005 San Bernardino California 92404
Sanofi-Aventis Investigational Site Number 840033 San Diego California 92103
Sanofi-Aventis Investigational Site Number 840031 Denver Colorado 80262
Sanofi-Aventis Investigational Site Number 840032 Stamford Connecticut 06902
Sanofi-Aventis Investigational Site Number 840034 Washington D.C. District of Columbia 20007
Sanofi-Aventis Investigational Site Number 840021 Washington D.C. District of Columbia 20010
Sanofi-Aventis Investigational Site Number 840001 Boca Raton Florida 33486
Sanofi-Aventis Investigational Site Number 840048 Boynton Beach Florida 33435
Sanofi-Aventis Investigational Site Number 840049 Jacksonville Florida 32224
Sanofi-Aventis Investigational Site Number 840061 Lakeland Florida 33805
Sanofi-Aventis Investigational Site Number 840060 Athens Georgia 30607
Sanofi-Aventis Investigational Site Number 840030 Boise Idaho 83712
Sanofi-Aventis Investigational Site Number 840024 Maywood Illinois 60153
Sanofi-Aventis Investigational Site Number 840062 Peoria Illinois 61615
Sanofi-Aventis Investigational Site Number 840039 Goshen Indiana 46526
Sanofi-Aventis Investigational Site Number 840054 Kansas City Kansas 66160-7321
Sanofi-Aventis Investigational Site Number 840057 Paducah Kentucky 42002
Sanofi-Aventis Investigational Site Number 840004 Metarie Louisiana 70006-290
Sanofi-Aventis Investigational Site Number 840045 Baltimore Maryland 21201
Sanofi-Aventis Investigational Site Number 840006 Detroit Michigan 48201
Sanofi-Aventis Investigational Site Number 840026 Lansing Michigan 48510
Sanofi-Aventis Investigational Site Number 840047 Saint Joseph Michigan 49805
Sanofi-Aventis Investigational Site Number 840009 Hackensack New Jersey 07601
Sanofi-Aventis Investigational Site Number 840044 Lake Success New York 11042
Sanofi-Aventis Investigational Site Number 840013 New York New York 10021
Sanofi-Aventis Investigational Site Number 840050 New York New York 10032
Sanofi-Aventis Investigational Site Number 840056 Rochester New York 14642
Sanofi-Aventis Investigational Site Number 840015 Syracuse New York 13210
Sanofi-Aventis Investigational Site Number 840041 Chapel Hill North Carolina 27599
Sanofi-Aventis Investigational Site Number 840007 Charlotte North Carolina 28204
Sanofi-Aventis Investigational Site Number 840019 Sylvania Ohio 43560
Sanofi-Aventis Investigational Site Number 840020 Bethlehem Pennsylvania 18015
Sanofi-Aventis Investigational Site Number 840065 Dunmore Pennsylvania 18512
Sanofi-Aventis Investigational Site Number 840058 Woonsocket Rhode Island 02895
Sanofi-Aventis Investigational Site Number 840052 Charleston South Carolina 29406
Sanofi-Aventis Investigational Site Number 840002 Knoxville Tennessee 37920
Sanofi-Aventis Investigational Site Number 840008 Houston Texas 77014
Sanofi-Aventis Investigational Site Number 840018 Houston Texas 77030
Sanofi-Aventis Investigational Site Number 840017 Lubbock Texas 79415
Sanofi-Aventis Investigational Site Number 840016 San Antonio Texas 78229
Sanofi-Aventis Investigational Site Number 840064 Temple Texas 76508
Sanofi-Aventis Investigational Site Number 840010 The Woodlands Texas 77380
Sanofi-Aventis Investigational Site Number 840036 Seattle Washington 98111
Sanofi-Aventis Investigational Site Number 840011 Madison Wisconsin 53792
Sanofi-Aventis Investigational Site Number 840025 Marshfield Wisconsin 54449
Sanofi-Aventis Investigational Site Number 840038 Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 108 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00625664, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2016 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00625664 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →